Millennium Management
MCRB icon

Millennium Management’s Seres Therapeutics MCRB Stock Holding History

Millennium Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,000
Closed -$4.29M – 7069
2021
Q2 		$4.29M Buy
+9,000
New +$3.8M ﹤0.01% 2957
2017
Q3 		– Sell
-2,000
Closed -$452K – 3715
2017
Q2 		$452K Hold
2,000
– – ﹤0.01% 2859
2017
Q1 		$451K Buy
+2,000
New +$406K ﹤0.01% 2868

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Millennium Management's MCRB Position: Q2 2025 in Review

Millennium Management sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 1,478 shares — an estimated $20.7K sold.

Millennium Management first reported a position in MCRB in Q2 2015 and held it in 33 quarters. The position peaked at $10.5M in Q4 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • Millennium Management reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 1,478 Seres Therapeutics shares in Q2 2025, an estimated $20.7K.
  • Millennium Management first reported a position in Seres Therapeutics in Q2 2015 and held it in 33 quarters.
  • Millennium Management's Seres Therapeutics position peaked at $10.5M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.